Compare CERS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERS | EOLS |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.0M | 529.1M |
| IPO Year | 1996 | 2018 |
| Metric | CERS | EOLS |
|---|---|---|
| Price | $2.30 | $7.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.13 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.8M | 612.3K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | $51,326,000.00 | ★ $297,176,000.00 |
| Revenue This Year | $20.82 | $12.44 |
| Revenue Next Year | $9.02 | $17.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.68 | 11.61 |
| 52 Week Low | $1.38 | $3.86 |
| 52 Week High | $3.47 | $9.31 |
| Indicator | CERS | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | 47.04 |
| Support Level | $2.05 | $7.59 |
| Resistance Level | $3.12 | $8.47 |
| Average True Range (ATR) | 0.10 | 0.32 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 20.41 | 46.18 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.